Trial reportPloS one2018
Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Fatty liver index (FLI): more than a marker of hepatic steatosis.Journal of physiology and biochemistry · 2024Pooled it
- Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles.Cancer biology & therapy · 2025Article
- Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agents.Discover oncology · 2025Review
- The relationship between lung cancer and hepatosteatosis in patients with biopsy-confirmed lung cancer diagnosis.Northern clinics of Istanbul · 2024Article
- Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Is Associated with Cervical Stromal Involvement in Endometrial Cancer Patients: A Cross-Sectional Study in South China.Current oncology (Toronto, Ont.) · 2023Article
- Impact of modifiable lifestyle risk factors for prostate cancer prevention: a review of the literature.Frontiers in oncology · 2023Review
- Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- A nationwide survey of the association between nonalcoholic fatty liver disease and the incidence of asthma in Korean adults.PloS one · 2022Article
- Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease.Journal of clinical and translational hepatology · 2021Review
- Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer.Clinical liver disease · 2021Review
- Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.British journal of cancer · 2020Article
- Nonalcoholic fatty liver disease burden: Australia, 2019-2030.Journal of gastroenterology and hepatology · 2020Article
- MiR-93/miR-375: Diagnostic Potential, Aggressiveness Correlation and Common Target Genes in Prostate Cancer.International journal of molecular sciences · 2020Article
- Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.Journal of clinical medicine · 2020Review
- Development and Validation of a Simple Index Based on Non-Enhanced CT and Clinical Factors for Prediction of Non-Alcoholic Fatty Liver Disease.Korean journal of radiology · 2020Article
- The Identification of Critical mFrontiers in genetics · 2020Article
- Article
- Extrahepatic Malignancies in Nonalcoholic Fatty Liver Disease.Current hepatology reports · 2019Article
- Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.PloS one · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowing evidence supports that prostate cancer (PCa) is a metabolic syndrome-related cancer, but the evidence is lacking regarding the association between nonalcoholic fatty liver disease (NAFLD) and PCa. We aimed to investigate whether PCa is related with NAFLD in Korean adults.
methodsData from the National Health Insurance Corporation between 2009 and 2012 were analyzed using multivariate logistic regression method. NALFD was defined based on the fatty liver index (FLI) and hepatic steatosis index (HSI). Newly diagnosed PCa was identified using the claims data.
resultsNAFLD based on FLI and HSI was identified in 2,002,375 (19%) and 2,629,858 (25%) of 10,516,985 subjects, respectively. Each FLI ≥ 60 and HSI ≥ 36 was independently associated with the development of PCa after adjusting for other confounders (hazard ratio (HR) 1.09, 95% CI: 1.06-1.12 and HR 1.19, 95% CI: 1.16-1.23). The association was more prominent among those who were older (FLI, ≥ 65 years old and HSI, ≥ 40 years old), were not currently smoking, were presently consuming alcohol (< 30g/day) and had null components of metabolic syndrome than each counterpart. Non-obese persons with NAFLD defined by HSI had a higher risk of developing PCa than those with body mass index > 25 Kg/m2.
conclusionsNAFLD defined by FLI or HSI may help identify high-risk individuals for developing PCa particular in the elderly, even in the absence of obesity or metabolic syndrome. Future studies on this topic should necessarily be repeated based on ultrasonographic findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.